SCHEMBL22977436

SCHEMBL22977436

Cc1ccc(-n2cnc(-c3nc(N[C@H]4CCN(C(=O)O)C[C@H]4C)ncc3C(F)(F)F)c2)c(C#N)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 9/20 0.36
▸ CDK2 P24941 9/20 0.36
▸ CCNT1 O60563 7/20 0.36
▸ CDK9 P50750 7/20 0.36
▸ CDK4 P11802 4/20 0.36
▸ CCND1 P24385 4/20 0.36
▸ CCND3 P30281 4/20 0.36
▸ CDK6 Q00534 4/20 0.36
▸ CDK7 P50613 3/20 0.36
▸ CCNH P51946 3/20 0.36
▸ MNAT1 P51948 3/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CCNB1 P14635 2/20 0.36
▸ CCNK O75909 7/20 0.34
▸ CDK12 Q9NYV4 7/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ MAPK3 P27361 3/20 0.34
▸ CHEK1 O14757 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22997743 0.92 CDK4 (0.40) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL29821604 0.92 CDK4 (0.40) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL22977076 0.83 CCNE1 (0.39) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL22997830 0.83 CCNE1 (0.48) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL22977445 0.83 CCNE1 (0.48) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL22997651 0.83 CCNK (0.43) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL30449674 0.83 CCNK (0.43) CCNE1CDK2CCNT1CDK9CDK4
SCHEMBL22977410 0.83 CCNK (0.43) CCNE1CDK2CCNT1CDK9CDK4
Hydrochloric Acid SCHEMBL22977438 0.83 CCNK (0.43) CCNE1CDK2CCNT1CDK9CDK4
Hydrochloric Acid SCHEMBL30449694 0.83 CCNK (0.43) CCNE1CDK2CCNT1CDK9CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-26 — — US disclosed
EP-4013750-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS Incyte Corporation (US) 2022-06-22 — — EP disclosed
WO-2021030537-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION (US) 2021-02-18 — — WO disclosed
US-20210047294-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2021-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047294-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CCNE1 43/4885CDK2 1/4885CCNT1 48/4885
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CCNE1 43/4885CDK2 1/4885CCNT1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback